These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 35720112)

  • 1. KCNN4 is a Potential Biomarker for Predicting Cancer Prognosis and an Essential Molecule that Remodels Various Components in the Tumor Microenvironment: A Pan-Cancer Study.
    Chen S; Su X; Mo Z
    Front Mol Biosci; 2022; 9():812815. PubMed ID: 35720112
    [No Abstract]   [Full Text] [Related]  

  • 2. KCNN4 is a potential prognostic marker and critical factor affecting the immune status of the tumor microenvironment in kidney renal clear cell carcinoma.
    Chen S; Wang C; Su X; Dai X; Li S; Mo Z
    Transl Androl Urol; 2021 Jun; 10(6):2454-2470. PubMed ID: 34295732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value and immunological role of CD44 in pan-cancer study.
    Chen S; Zhang S; Chen S; Ma F
    Sci Rep; 2023 Apr; 13(1):7011. PubMed ID: 37117249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer.
    Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W
    Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ARPC2: A Pan-Cancer Prognostic and Immunological Biomarker That Promotes Hepatocellular Carcinoma Cell Proliferation and Invasion.
    Huang S; Dong C; Li D; Xu Y; Wu J
    Front Cell Dev Biol; 2022; 10():896080. PubMed ID: 35733852
    [No Abstract]   [Full Text] [Related]  

  • 6. Pan-cancer analysis of CREB3L1 as biomarker in the prediction of prognosis and immunotherapeutic efficacy.
    Lin Z; Wu Y; Xiao X; Zhang X; Wan J; Zheng T; Chen H; Liu T; Tang X
    Front Genet; 2022; 13():938510. PubMed ID: 36171879
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of ARRB1 in prognosis and immunotherapy: A Pan-Cancer analysis.
    Ye Y; Jiang H; Wu Y; Wang G; Huang Y; Sun W; Zhang M
    Front Mol Biosci; 2022; 9():1001225. PubMed ID: 36213111
    [No Abstract]   [Full Text] [Related]  

  • 8. A Pan-Cancer Analysis Reveals the Prognostic and Immunotherapeutic Value of Stanniocalcin-2 (STC2).
    Jiang ZH; Shen X; Wei Y; Chen Y; Chai H; Xia L; Leng W
    Front Genet; 2022; 13():927046. PubMed ID: 35937984
    [No Abstract]   [Full Text] [Related]  

  • 9. Insights into the Oncogenic, Prognostic, and Immunological Role of BRIP1 in Pan-Cancer: A Comprehensive Data-Mining-Based Study.
    Liu Y; Wu X; Feng Y; Jiang Q; Zhang S; Wang Q; Yang A
    J Oncol; 2023; 2023():4104639. PubMed ID: 37153833
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Wu G; Chen M; Ren H; Sha X; He M; Ren K; Qi J; Lin F
    Front Cell Dev Biol; 2022; 10():930933. PubMed ID: 35874816
    [No Abstract]   [Full Text] [Related]  

  • 11. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Analysis of RELL2 as a Potential Biomarker Associated with Tumor Immune Infiltrating Cells in a Pan-Cancer Analysis.
    Musha K; Ge X; Ablikim N; Lu B; Chen C; Huang J
    Dis Markers; 2022; 2022():5009512. PubMed ID: 35634441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BOP1 Used as a Novel Prognostic Marker and Correlated with Tumor Microenvironment in Pan-Cancer.
    Li W; Song P; Zhao M; Gao L; Xie J; You C
    J Oncol; 2021; 2021():3603030. PubMed ID: 34603446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zic Family Member 2 (ZIC2): a Potential Diagnostic and Prognostic Biomarker for Pan-Cancer.
    Lv Z; Qi L; Hu X; Mo M; Jiang H; Fan B; Li Y
    Front Mol Biosci; 2021; 8():631067. PubMed ID: 33665207
    [No Abstract]   [Full Text] [Related]  

  • 15. Pan-Cancer Analysis Revealed
    Liu J; Wang Y; Yin J; Yang Y; Geng R; Zhong Z; Ni S; Liu W; Du M; Yu H; Bai J
    J Oncol; 2022; 2022():3477148. PubMed ID: 35069733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifies microtubule-binding protein
    Wang W; Zhang J; Wang Y; Xu Y; Zhang S
    Comput Struct Biotechnol J; 2022; 20():3322-3335. PubMed ID: 35832625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights Into the Prognostic Value and Immunological Role of NAAA in Pan-Cancer.
    Huang D; Shen J; Zhai L; Chen H; Fei J; Zhu X; Zhou J
    Front Immunol; 2021; 12():812713. PubMed ID: 35069601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pan-Cancer Analysis of the N6-Methyladenosine Eraser FTO as a Potential Prognostic and Immunological Biomarker.
    Zhao C; Liu Y; Ju S; Wang X
    Int J Gen Med; 2021; 14():7411-7422. PubMed ID: 34744452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
    Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-Cancer Analysis Identified CD93 as a Valuable Biomarker for Predicting Patient Prognosis and Immunotherapy Response.
    Tong W; Wang G; Zhu L; Bai Y; Liu Z; Yang L; Wu H; Cui T; Zhang Y
    Front Mol Biosci; 2021; 8():793445. PubMed ID: 35265666
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.